Ocugen (OCGN) director Blaise Coleman receives 170,100 stock options at $1.22

Rhea-AI Filing Summary

Ocugen, Inc. director Blaise Coleman received a new stock option grant covering 170,100 shares of common stock. The option has an exercise price of $1.22 per share and expires on June 11, 2036. This is a compensation-related award, not an open-market purchase.

According to the terms, the option vests upon the earlier of June 11, 2027 or Ocugen’s next annual meeting of stockholders, provided Coleman continues to serve through the applicable vesting date. Following this grant, he holds 170,100 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Coleman Blaise

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	170,100	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 170,100 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 170,100 shares Exercise price: $1.22 per share Expiration date: June 11, 2036 +2 more

5 metrics

Option grant size 170,100 shares Stock options granted to director Blaise Coleman

Exercise price $1.22 per share Strike price of stock option grant

Expiration date June 11, 2036 Option term for 170,100-share grant

Vesting outside date June 11, 2027 Latest vesting date, or earlier at next annual meeting

Total options after grant 170,100 options Holdings following the reported transaction

Key Terms

Stock Option (Right to Buy), exercise price, vesting date, annual meeting of stockholders, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "1.2200""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting date financial

"subject to the Reporting Person's continued service through the applicable vesting date"

annual meeting of stockholders regulatory

"Ocugen, Inc.'s next annual meeting of stockholders"

expiration date financial

"expiration_date: "2036-06-11T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Coleman Blaise

(Last) (First) (Middle)

C/O OCUGEN, INC.

11 GREAT VALLEY PARKWAY

(Street)

MALVERN PENNSYLVANIA 19355

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Ocugen, Inc. [ OCGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.22	06/11/2026		A		170,100		(1)	06/11/2036	Common Stock	170,100	$0	170,100	D

Explanation of Responses:

1. The option vests upon the earlier of (a) June 11, 2027 or (b) Ocugen, Inc.'s next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date.

	/s/ Shankar Musunuri, attorney-in-fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Ocugen (OCGN) report for Blaise Coleman?

Ocugen reported that director Blaise Coleman received a stock option grant for 170,100 shares of common stock. The award is a compensation-related option, not an open-market share purchase or sale, and gives him the right to buy shares at a fixed exercise price.

How many Ocugen (OCGN) stock options were granted to Blaise Coleman and at what price?

Blaise Coleman was granted options covering 170,100 shares of Ocugen common stock at an exercise price of $1.22 per share. This means he can later buy up to 170,100 shares at $1.22, subject to vesting conditions and the option’s long-term expiration date.

When do Blaise Coleman’s Ocugen (OCGN) stock options vest?

The options vest on the earlier of June 11, 2027 or Ocugen’s next annual meeting of stockholders. Vesting also requires Coleman’s continued service through the applicable vesting date, tying the award to his ongoing role with the company over time.

When do Blaise Coleman’s Ocugen (OCGN) stock options expire?

The stock options granted to Blaise Coleman expire on June 11, 2036. After that date, any unexercised portion of the 170,100-share grant can no longer be used to buy Ocugen common stock at the fixed $1.22 per share exercise price.

Is Blaise Coleman’s Ocugen (OCGN) Form 4 transaction a stock purchase or sale?

The Form 4 shows a grant of stock options, not a direct stock purchase or sale. Coleman acquired a right to buy 170,100 shares at $1.22 per share as part of his director compensation, rather than trading existing Ocugen common stock in the open market.